The truncated glucocorticoid receptor in the P1798 mouse lymphosarcoma is associated with resistance to glucocorticoid lysis but not to other glucocorticoid-induced functions.
Glucocorticoid receptors in lines of the P1798 mouse lymphosarcoma either sensitive or resistant to glucocorticoid-induced lysis have been characterized and their functional significance determined. The glucocorticoid receptor from the cortisol-sensitive tumor is an Mr approximately 98,000 protein with a Stokes radius of 7.4 nm in the oligomeric, non-DNA-binding state and 5.6 nm in the transformed, DNA-binding state. This receptor binds glucocorticoid and reacts with the BUGR-2 monoclonal antibody. In contrast, two abnormal receptor species were identified in the cortisol-resistant tumor. One is an Mr approximately 98,000 non-steroid-binding but immunologically reactive protein. The other is an Mr approximately 45,000 species which contains both steroid- and DNA-binding sites but exhibits little or no reactivity with BUGR-2, suggesting that its NH2 terminus is truncated in a region within or adjacent to the BUGR epitope. This species had Stokes radii of 5.8 and 3.5 nm in nontransformed and transformed states, respectively. In both tumor lines, glucocorticoids stimulated the activities of glutamine synthetase and 5'-nucleotidase and the synthesis of glucocortin. However, glucocorticoid-induced tumor regression occurred only in the cortisol-sensitive tumor. Additionally, the glucocorticoid inducibility of a specific protein in the sensitive, but not in the resistant, tumor was demonstrated, as well as the presence of a protein specific to the resistant line. Taken together, these results suggest that the truncated glucocorticoid receptor in the P1798 lymphosarcoma is functional, although possibly in a more restricted gene-specific manner, and that the lysis defect, while possibly resulting from a truncated receptor, may also result from the inability of glucocorticoids to induce a critical protein in the pathway of programmed cell death and/or from the presence of a protein which inhibits the lytic response.
Ip
M M
MM
Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263.
Shea
W K
WK
Sykes
D
D
Young
D A
DA
D015720:5'-Nucleotidase / Q000096:biosynthesis; D000818:Animals; D001667:Binding, Competitive; D003907:Dexamethasone / Q000031:analogs & derivatives / Q000378:metabolism; D004351:Drug Resistance; D004790:Enzyme Induction; D005938:Glucocorticoids / Q000494:pharmacology*; D005974:Glutamate-Ammonia Ligase / Q000096:biosynthesis; D006854:Hydrocortisone / Q000494:pharmacology; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry* / Q000201:enzymology; D051379:Mice; D008970:Molecular Weight; D014176:Protein Biosynthesis; D011506:Proteins; D011965:Receptors, Glucocorticoid / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D014407:Tumor Cells, Cultured
D005938:Glucocorticoids; D011506:Proteins; D011965:Receptors, Glucocorticoid; C047380:glucocortin protein, mouse; D003907:Dexamethasone; D015720:5'-Nucleotidase; D005974:Glutamate-Ammonia Ligase; C031710:dexamethasone 21-methanesulfonate; D006854:Hydrocortisone